SVB Securities analyst Daina Graybosch maintained a Buy rating on Innate Pharma (IPHA – Research Report) yesterday. The company’s shares closed yesterday at $2.03.
According to TipRanks, Graybosch is an analyst with an average return of -22.0% and a 25.93% success rate. Graybosch covers the Healthcare sector, focusing on stocks such as Innate Pharma, Merck & Company, and Nektar Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Innate Pharma with a $8.50 average price target, implying a 318.72% upside from current levels. In a report released yesterday, H.C. Wainwright also maintained a Buy rating on the stock with a $11.50 price target.
See the top stocks recommended by analysts >>
IPHA market cap is currently $170M and has a P/E ratio of -2.71.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Innate Pharma SA is a clinical-stage biotechnology company. The company is engaged in discovering and developing first-in-class therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients. It specializes in immuno-oncology, a new therapeutic field that is changing cancer treatment by mobilizing the power of the body’s immune system to recognize and kill cancer cells. The company’s revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies.
